Abstract��Ideal preparation of cancer therapy could specifically target to tumor cells, serving as safe and effective drug delivery system. With peculiar molecular recognition ability, aptamers become the most promising biological target molecules. This review was based on representative literatures,and the data was summarized and analyzed. It summarizes the latest research progress of aptamers modified targeted tumor preparation in the past five years from tethered way and carriers type, and the existing problems are analyzed and prospected.
REINEMANN C, STREHLITZ B. Aptamer-modified nanoparticles and their use in cancer diagnostics and treatment [J]. Swiss Medical Weekly, 2014, 144:w13908.
[2]
ZHOU G, WILSON G, HEBBARD L, et al. Aptamers:a promising chemical antibody for cancer therapy [J]. Oncotarget, 2016, 7 (12):13446-13463.
[3]
DARMOSTUK M, RIMPELOVA S, GBELCOVA H, et al. Current approaches in SELEX:an update to aptamer selection technology [J]. Biotechnol Adv, 2015, 33 (6 Pt 2):1141-1161.
[4]
OZER A, PAGANO J M, LIS J T, et al. New technologies provide quantum changes in the scale, speed, and success of SELEX methods and aptamer characterization [J]. Mol Ther Nucleic Acids, 2014, 3:e183.
[5]
ZHOU J, ROSSI J J. Evolution of cell-type-specific RNA aptamers via live cell-based SELEX [J]. Methods Mol Biol, 2016, 1421:191-214.
[6]
LAVU P S, MONDAL B, RAMLAL S, et al. Selection and characterization of aptamers using a modified Whole-Cell Bacterium SELEX for the detection of salmonella enterica serovar typhimurium [J]. ACS Comb Sci, 2016, 18 (6):292-301.
[7]
ZHU B, HERNANDEZ A, TAN M, et al. Synthesis of 2'-Fluoro RNA by Syn5 RNA polymerase [J]. Nucleic Acids Res, 2015,43 (14):e94.
[8]
MEYER A J, GARRY D J, HALL B, et al. Transcription yield of fully 2'-modified RNA can be increased by the addition of thermostabilizing mutations to T7 RNA polymerase mutants [J]. Nucleic Acids Res, 2015, 43 (15):7480-7488.
[9]
LAURIDSEN L H, ROTHNAGEL J A, VEEDU R N. Enzymatic recognition of 2'-modified ribonucleoside 5'-triphosphates:towards the evolution of versatile aptamers [J]. Chembiochem, 2012, 13 (1):19-25.
[10]
LAPA S A, CHUDIONOV A V, TIMOFEEV E N. The toolbox for modified aptamers [J]. Mol Biotechnol, 2016,58(2):79-92.
[11]
LIU B, ZHANG J, LIAO J, et al. Aptamer-functionalized nanoparticles for drug delivery [J]. J Biomed Nanotechnol, 2014, 10 (11):3189-3203.
[12]
HUANG Y F, SHANGGUAN D, LIU H, et al. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells [J]. Chembiochem,2009, 10 (5):862-868.
[13]
TRINH T L, ZHU G, XIAO X, et al. A synthetic aptamer-drug adduct for targeted liver cancer therapy [J]. PLoS One, 2015, 10 (11):e0136673.
[14]
YANG L, ZHANG X, YE M, et al. Aptamer-conjugated nanomaterials and their applications [J]. Adv Drug Deliv Rev, 2011, 63 (14-15):1361-1370.
[15]
WANG J, ZHU G, YOU M, et al. Assembly of aptamer switch probes and photosensitizer on gold nanorods for targeted photothermal and photodynamic cancer therapy [J]. ACS Nano, 2012, 6(6):5070-5077.
[16]
SHIAO Y S, CHIU H H, WU P H, et al. Aptamer-functionalized gold nanoparticles as photoresponsive nanoplatform for co-drug delivery [J]. ACS Appl Mater Interfaces, 2014, 6 (24), 21832-21841.
[17]
LUO Y L, SHIAO Y S, HUANG Y F. Release of photoactivatable drugs from plasmonic nanoparticles for targeted cancer therapy [J]. ACS Nano, 2011, 5 (10):7796-7804.
[18]
PALA K, SERWOTKA A, JELEN F, et al. Tumor-specific hyperthermia with aptamer-tagged superparamagnetic nanoparticles [J]. Int J Nanomed, 2014, 9(1):67-76.
[19]
AZHDARZADEH M, ATYABI F, SAEI A A, et al. Theranostic MUC-1 aptamer targeted gold coated superparamagnetic iron oxide nanoparticles for magnetic resonance imaging and photothermal therapy of colon cancer [J]. Colloids Surf B Biointerfaces, 2016, 143:224-232.
[20]
HE Z M, ZHANG P H, LI X, et al. Targeted DNAzyme-nanocomposite probe equipped with built-in Zn2+ arsenal for combined treatment of gene regulation and drug delivery [J]. Sci Rep, 2016, 6:22737.
[21]
SAVLA R, TARATULA O, GARBUZENKO O, et al. Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer [J]. J Controlled Release, 2011, 153 (1):16-22.
[22]
TAGHAVI S, HASHEMNIA A, MOSAFFA F, et al. Preparation and evaluation of polyethylenimine-functionalized carbon nanotubes tagged with 5TR1 aptamer for targeted delivery of Bcl-xL shRNA into breast cancer cells [J]. Colloids Surf B Biointerfaces, 2016, 140:28-39.
[23]
XIE X, LI F, ZHANG H, et al. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery [J]. Eur J Pharm Sci, 2016, 83:28-35.
[24]
TANG Y, HU H, ZHANG M G, et al. An aptamer-targeting photoresponsive drug delivery system using "off-on" graphene oxide wrapped mesoporous silica nanoparticles [J]. Nanoscale, 2015, 7(14):6304-6310.
[25]
MOOSAVIAN S A, ABNOUS K, BADIEE A, et al. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model [J]. Colloids Surf B Biointerfaces, 2016, 139:228-236.
[26]
SONG X, REN Y, ZHANG J, et al. Targeted delivery of doxorubicin to breast cancer cells by aptamer functionalized DOTAP/DOPE liposomes [J]. Oncol Rep, 2015, 34 (4):1953-1960.
LI X, YU Y, JI Q, et al. Targeted delivery of anticancer drugs by aptamer AS1411 mediated Pluronic F127/cyclodextrin-linked polymer composite micelles [J]. Nanomedicine, 2015, 11 (1):175-184.
[29]
GUO J, GAO X, SU L, et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery [J]. Biomaterials, 2011, 32 (31):8010-8020.
[30]
PROW T W, YU C, HU Y, et al. Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro [J]. PLoS One, 2011, 6 (9):e24077.
[31]
HU X, TULSIERAM K L, ZHOU Q, et al. Polymeric nanoparticle-aptamer bioconjugates can diminish the toxicity of mercury in vivo [J]. Toxicol Lett, 2012, 208 (1):69-74.
[32]
ARAVIND A, JEYAMOHAN P, NAIR R, et al. AS1411 Aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery [J]. Biotechnol Bioeng, 2012, 109 (11):2920-2931.
[33]
LI L, XIANG D, SHIGDAR S, et al. Epithelial cell adhesion molecule aptamer functionalized PLGA-lecithin-curcumin-PEG nanoparticles for targeted drug delivery to human colorectal adenocarcinoma cells [J]. Int J Nanomed, 2014, 9(1):1083-1096.
[34]
GHASEMI Z, DINARVAND R, MOTTAGHITALAB F, et al. Aptamer decorated hyaluronan/chitosan nanoparticles for targeted delivery of 5-fluorouracil to MUC1 overexpressing adenocarcinomas [J]. Carbohydr Polym, 2015, 121:190-198.
[35]
ZHAO N, BAGARIA H G, WONG M S, et al. A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphoma [J]. J Nanobiotechnol, 2011, 9:2.
[36]
YANG J, XIE S X, HUANG Y, et al. Prostate-targeted biodegradable nanoparticles loaded with androgen receptor silencing constructs eradicate xenograft tumors in mice [J]. Nanomedicine (Lond), 2012, 7 (9):1297-1309.
[37]
ASKARIAN S, ABNOUS K, TAGHAVI S, et al. Cellular delivery of shRNA using aptamer-conjugated PLL-alkyl-PEI nanoparticles [J]. Colloids Surf B Biointerfaces, 2015, 136:355-364.
[38]
TAGHDISI S M, DANESH N M, RAMEZANI M, et al. Double targeting and aptamer-assisted controlled release delivery of epirubicin to cancer cells by aptamers-based dendrimer in vitro and in vivo [J]. Eur J Pharm Biopharm, 2016, 102:152-158.
[39]
ZHANG H, MA Y, XIE Y, et al. A controllable aptamer-based self-assembled DNA dendrimer for high affinity targeting, bioimaging and drug delivery [J]. Sci Rep, 2015, 5:10099.
[40]
WU X, DING B, GAO J, et al. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy [J]. Int J Nanomed, 2011, 6:1747-1756.
[41]
WU J, SONG C, JIANG C, et al. Nucleolin targeting AS1411 modified protein nanoparticle for antitumor drugs delivery [J]. Mol Pharm, 2013, 10 (10):3555-3563.
[42]
GILBOA-GEFFEN A, HAMAR P, LE M T, et al. Gene knockdown by EpCAM aptamer-siRNA chimeras suppresses epithelial breast cancers and their tumor-initiating cells [J]. Mol Cancer Ther,2015, 14 (10):2279-2291.
[43]
SUBRAM N, KANWAR J R, KANWAR R K, et al. EpCAM aptamer-siRNA chimera targets and regress epithelial cancer [J]. PLoS One, 2015, 10(7):e0132407.
[44]
NI X, ZHANG Y, ZENNAMI K, et al. Systemic administration and targeted radiosensitization via chemically synthetic aptamer-siRNA chimeras in human tumor xenografts [J]. Mol Cancer Ther, 2015, 14 (12):2797-2804.
2017, Vol. 52 
